In conclusion, GL-PP has the potential to treat DOX-induced kidney disorders by reducing inflammation and fibrosis by inhibiting PRR, regulating RAS and NOX4, and lowering the production of inflammatory fibrotic factors. Here, ATP6AP2 is linked to kidney disorder.